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Early diagnosis is an important aspect of contemporary cancer prevention and control strategies, as the majority of
patients are diagnosed following symptomatic presentation. The nature of presenting symptoms can critically
influence the length of the diagnostic intervals from symptom onset to presentation (the patient interval), and from
first presentation to specialist referral (the primary care interval). Understanding which symptoms are associated
with longer diagnostic intervals to help the targeting of early diagnosis initiatives is an area of emerging research.
In this Review, we consider the methodological challenges in studying the presenting symptoms and intervals to
diagnosis of cancer patients, and summarize current evidence on presenting symptoms associated with a range of
common and rarer cancer sites. We propose a taxonomy of cancer sites considering their symptom signature and
the predictive value of common presenting symptoms. Finally, we consider evidence on associations between
symptomatic presentations and intervals to diagnosis before discussing implications for the design, implementa-
tion, and evaluation of public health or health system interventions to achieve the earlier detection of cancer.
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Diagnosing cancer earlier is a critical aim of contemporary cancer
control policies. Screening interventions can achieve asymptomatic
detection but are currently only available for a limited number of cancer
sites, and their effectiveness is further constrained by limited sensitivity
and both suboptimal and unequal uptake. This means that the majority
of cancer patients continue to be diagnosed following symptomatic
presentation, for whom timely diagnosis is associated with better clinical
and patient-reported outcomes [1–5]. Diagnosing cancer at an earlier
stage is also likely to be cost-effective given the increasing costs of novel
drug therapies for advanced stage disease [6]. These considerations
highlight the need for efforts aimed at shortening intervals to diagnosis
in patients who present with symptoms.
Substantial variation in measures of diagnostic timeliness exists between
patients with different cancers [7–10]. Much of this variation has been
attributed to the differing nature, frequency, and combinations of
presenting symptoms (the ‘symptom signature’) of each cancer site (asdefined in Box 1), though empirical evidence supporting this explanation is
sparse. Presenting symptoms can influence the time from symptom onset
to first presentation (the patient interval) and the time from first
presentation to subsequent referral to specialist care (the primary care
interval) [11]. Studying how different symptoms are associated with the
length of these two intervals is therefore a priority for early diagnosis
research.
ox 1
efining symptom signature and diagnostic difficulty
In this Review, we make frequent use of two terms:
symptom signature and diagnostic difficulty.
Symptom signature denotes the nature and relative
frequency of symptoms (or symptom combinations) reported
at presentation by patients later diagnosed with a particular
cancer [13,14]. We describe symptom signatures as being
‘narrow’ when most patients present with a particular
symptom (as is the case for breast lump in the context of
breast cancer) or ‘broad’ when patients present with a larger
range of symptoms (as is the case for colorectal cancer).
The term diagnostic difficulty (of a given cancer
site) has previously been used to characterize cancer sites
as “harder-to-suspect” (e.g. multiple myeloma, pancreatic
cancer) or “easier-to-suspect” (e.g. breast cancer, mela-
noma) based on the profile of presenting symptoms [13].
It represents the perceived predictive value for cancer of
the presenting symptoms of the ‘average’ patient.
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DBox 2
Approaches to measuring presenting symptoms in cancer patie
Self-reported symptom information.
Information on presenting symptoms can be directly el
questionnaires [32,33]. Such methods can elicit valuable firs
Patients may be prompted to identify their presenting sym
them without any prompting (symptom recall), which can af
consider their symptom status in respect of calendar ‘landm
significance) may be helpful [34]. Studies can also be distin
diagnosis. Collecting data about presenting symptoms after di
can lead to both recall and survivorship bias. The latter results
presenting symptoms could be different to those of the studie
(before a diagnosis of cancer is made) has the advantage of
Records-based symptom information.
Alternatively, information on presenting symptoms can b
physician) and captured as part of the patients' health record
[42–45].
In principle, studies collecting symptom information from
as information on presenting symptoms is collected prospecti
critically rely on the symptoms both being elicited during the
assumptions may not be met [46,47]. Additionally, psychosoc
time pressures during the consultation [50] may prevent comp
can also be less sensitive to qualitative distinctions in symp
symptoms are recorded.We discuss methodological challenges in capturing data on symptoms
at presentation and intervals to diagnosis and subsequently examine the
symptom signatures of cancer sites and how this relates to diagnostic
difficulty (Box 1). Diagnostic difficulty is related to the positive predictive
value (PPV) of a symptom for a given disease, which is the proportion of
all patients with the same symptomwhowill be found to have the disease.
While PPV is a continuous measure, explicit threshold categories fornt po
icited
t-han
ptom
fect
ark’
guis
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in un
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mini
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s [3
patie
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lete
tominvestigation or other assessment can be considered, though until recently
there have been no such applications in policy. Since 2015, the English
National Institute for Health and Care Excellence (NICE) has mandated
referral for specialist assessment for patients presenting in primary care
with symptoms associated with a PPV for cancer that exceeds 3% [12].
This provides a practical reference point for judging the clinical
significance of a symptom in the context of cancer diagnosis and has
informed our interpretation throughout this Review.
Finally, we summarize available evidence on the association between
symptomatic presentations and diagnostic intervals and discuss how this
evidence could inform the design of early diagnosis interventions.
How Can Presenting Symptoms and Intervals
Before Diagnosis be Measured?
Capturing information on symptoms is challenging, as the majority
cannot be objectively observed and their appraisal by individuals is
influenced by sociocultural factors such as level of education and health
literacy (including awareness of likely cancer symptoms), cancer fear, or
fatalism [14,15]. When more than one symptom is experienced, the
combination of symptoms could also influence appraisal and
help-seeking. Additionally, several symptoms may have conflicting or
overlapping meanings in lay and professional language, and this is
reflected in heterogeneous terminology in published literature. For
example, abdominal bloating (uncomfortable sensation of fullness) and
distension (visible increase in abdominal girth) have been used
interchangeably [16,17], while ‘change in bowel habit’ is often used
by clinicians to denote a clinical suspicion of colorectal cancer beyond
the presence of constipation or diarrhea alone [18]. Further,
heterogeneity exists within certain nonspecific symptoms: ‘abdominal
pain,’ for example, encompasses a range of presentations that vary
greatly in nature, intensity, duration, and temporal evolution.pulations
from patients through semistructured interviews [26–31] or
d insights into the symptomatic and diagnostic experience.
s from a predefined list (symptom recognition) or to describe
the degree of recall inaccuracies or bias. Prompting patients to
dates (such as public holidays or events and dates of personal
hed by whether the information is collected before or after the
sis is more convenient due to easier identification of cases but it
derrepresentation of cancer patients with poor prognosis, whose
tients [35]. In comparison, collecting information prospectively
mizing such potential biases [36–38].
corded during healthcare encounters (e.g., with a primary care
9–41]. Both coded and free-text information may be extracted
nt records are less prone to the risk of selection and recall bias,
and prior to diagnosis for all patients. However, such methods
ultation and being accurately recorded; in many instances, these
arriers (such as embarrassment [47–49]) and perceived or actual
disclosure of certain symptoms to the doctor. Coded information
experience such as temporal evolution, particularly if multiple
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experienced by cancer patients. Existing methods rely on the validity of
the recall of particular dates of significance along the diagnostic pathway
including the date of symptom onset, the date of first relevant
symptomatic presentation (help-seeking), and the date of first referral
to secondary care [11].
Two principal study designs have been described to examine
diagnostic intervals: collecting self-reported information from patients
and extracting information from patients' health records [9,11]. We
propose that these approaches are also relevant to the study of presenting
symptoms (Box 2). Inconsistencies between self-reported and
records-based information have been described, reflecting that both
approaches have limitations [19–22]. Nonetheless, medical record
studies offer the opportunity to examine prediagnostic symptoms (and
intervals) in large and representative samples of patients, additionally
facilitating the study of patients with rarer cancers [10,23–25].What are the Symptom Signatures of Different
Cancer Sites?
Understanding the nature and relative frequency of presenting symptoms
associated with different cancer sites is necessary before investigating how
symptoms may influence diagnostic timeliness. We therefore reviewed
the literature to examine the symptom signature of common and rarer
cancers (see Box 3) and present the findings here. We consider cancers inBox 3
Data sources and findings of literature review on the symptom signatures
Methodology
We searched for studies describing the frequency of presenti
records or prospectively collected self-reported information, sup
describing self-reported symptoms captured retrospectively (after d
pediatric, teenager, and young adult cancer patient populations
excluded as they were deemed not comparable. All retrieved stu
cancer site were additionally examined for information on associ
There is no standard assessment tool for risk of bias in observation
based on theREporting of studies Conducted usingObservational Rou
of Diagnostic Accuracy Studies 2nd version (QUADAS-2) checklist
across six dimensions: setting, study population, symptoms, external v
was used to further exclude any studies that had three or more dimen
Summary of findings
We identified a total of 41 studies including information on presen
symptom frequencies by cancer site). All included studies were based
the predictive value of symptoms: for such studies, the sample size
extracted. Of the included studies, 18 (44%) had low risk of bias acro
across two dimensions (study population and symptom information) (
exception of colorectal, esophagogastric, and renal tract cancers, which
related to colorectal cancer (eight studies, Table S3.4), pancreatic cance
only a single publication was identified for five cancers (brain, cervic
No evidence on the frequency of presenting symptoms before dia
cancer; liver cancer;melanoma;mesothelioma; oral cancer; penile canc
vaginal cancer; and vulval cancer.
Of the 41 studies included in the Review, only four also contained e
to diagnosis [36–38,44]. One study was not included in the considera
through a combination of recall and recognition; however, evidenc
considered here [22].three groups based on symptom signatures, taking into account symptom
heterogeneity (the ‘breadth’ of the symptom signature) and their
predictive value (see Figure 1).
Cancers With a Narrow Symptom Signature
In this category, we consider several cancers where the majority of
patients present with one symptom with adequately strong association
with a given cancer (these are also known as ‘alarm’ symptoms). For
example, the majority of women diagnosed with breast cancer initially
present with a breast lump, which is associated with a relatively high
predictive value for cancer; see Table 1 [44,59,60]. Similarly, most
bladder cancer patients present with macroscopic (visible, frank)
hematuria (Table S3.1) [43,61,62].
Likewise, the symptomatic presentations of thyroid cancer, melanoma,
testicular cancer, penile cancer, vaginal cancer, vulval cancer, and sarcoma
are also narrow and are likely to have meaningfully high predictive values,
although empirical documentation of the symptom signatures of these
cancers is limited [63,64]. Importantly, a relatively narrow symptom
signature does not necessarily guarantee swift or easy diagnostic resolution
for all patients. Firstly, the nature of the symptoms associatedwith sarcomas
(soft tissue lump or bone pain) suggests the level of diagnostic difficulty
should be low, but the relative rarity of sarcomas among the general
population means that alternative diagnoses are often provided [65].
Raising awareness of these symptoms could achieve earlier diagnosis for this
cancer type given the reasonable predictive values for malignancy [66], butof cancer and associations between symptoms and diagnostic intervals
ng symptoms of cancer patients based on either primary care
plemented by expert knowledge of relevant evidence. Studies
iagnosis) were excluded due to the high risk of bias. Studies on
and studies based in low- and middle-income settings were
dies providing evidence regarding the symptom signature of a
ations between symptoms and diagnostic intervals.
al nonrandomized studies, and so we developed a risk of bias tool
tinely-collected healthData (RECORD) and theQualityAssessment
s [51,52]. The resulting quality appraisal tool assessed risk of bias
alidity, data cleaning, and other sources of bias (Table S1). This tool
sions with “high” risk of bias.
ting symptoms for 16 cancer sites (see Supplementary Material for
in the UK and were mostly case-control or cohort studies examining
and symptom frequency relevant to cases (and not controls) were
ss all examined dimensions, while 11 studies had high risk of bias
Table S2). Nearly all studies focused on single cancer sites, with the
were treated as single entities, respectively [53–58]. Most evidence
r (six studies, Table S3.9), and lung cancer (five studies, Table S3.6);
al, endometrial, leukemia, and myeloma).
gnosis could be identified for the following 12 cancers: laryngeal
er; sarcoma; small intestinal cancer; testicular cancer; thyroid cancer;
vidence on associations between individual symptoms and intervals
tion of symptom signatures as symptom information was collected
e pertaining to symptom-specific diagnostic timeliness has been
Figure 1. Taxonomy of cancer site–specific symptom signatures
based on nature and frequency of presenting symptoms and their
associated predictive value for malignancy at presentation. CNS:
Central Nervous System.
Table 1. Population-Based Estimates of the Frequencies of Presenting Symptoms Among Breast
Cancer Patients [44,59,60]
Study Setting/Source
of Data
Study
Period
Sample
Size
Study
Population
Age/Range
Symptoms
168 Symptoms and Timeliness in Cancer Patients Koo et al. Neoplasia Vol. 20, No. xx, 2018the cost-effectiveness of a population-wide intervention for such rare cancers
would be a concern. Secondly, a minority of patients with ‘narrow
symptom signature’ cancers will have atypical presentations, which tend to
be associated with a longer time to presentation and referral [44,67].Walker et al.,
2014
Primary care,
CPRD data
(Read coded)
2000-09 3166 40+ years Breast lump 44.1%
Breast pain 2.4%
Nipple retraction 1.0%
Nipple discharge 1.0%
Redaniel et al.,
2015 *
Primary care,
CPRD data
(Read coded)
1998-09 8544 15+ years Breast lump 93.5%
Breast pain 4.6%
Nipple distortion 1.5%
Nipple eczema 0.2%
Breast skin changes 0.2%
Bloody nipple 0.01%
Koo et al.,
2017 †
Primary care,
audit data
(free text)
2009-10 2316 20+ years Breast lump 83%
Nipple abnormalities 6.8%
Breast pain 6.4%
Breast skin abnormalities 2.0%
Axillary lump 1.2%
Breast ulceration 1.1%
Back pain 1.0%
Breast contour
abnormalities 0.7%
Breast infection or
inflammation 0.6%
Breast swelling 0.6%
Musculoskeletal pain 0.6%
Breathlessness 0.5%
Breast rash 0.4%
* All symptom frequencies calculated based on the number of breast cancer patients who had presented
with a breast symptom, excluding those who were diagnosed following disclosure of family history (i.e., in the
absence of any symptoms).
† Symptoms in 10 or more women listed only; further symptoms listed in Supplementary files of original paper.Cancers With a Broad Symptom Signature
In this category, we consider cancer sites characterized by a broad
symptom signature. For some cancers, this includes certain alarm
symptoms (e.g., colorectal, lung, pancreatic, esophagogastric, and
ovarian cancers), while for other cancers, presenting symptoms are
chiefly nonspecific (e.g., hematological malignancies, and brain and
CNS cancers).
Broad Symptom Signature, Varying Predictive Value. Many
common cancers have broad symptom signatures consisting of multiple
symptoms, of which only few (e.g. one or two) are alarm symptoms that
are strongly predictive of cancer. For example, eight studies report rectal
bleeding, which has relatively high predictive value, as a common
presenting symptom of colorectal cancer, although estimates vary
substantially (16%-60%) [18,38,68–73]. Other common presenting
symptoms among colorectal cancer patients include abdominal pain,
diarrhea, and constipation, which are associated with much lower
predictive values and greater diagnostic difficulty (Table S3.4). Lung
cancer also has a broad symptom signature with symptoms of varying
predictive value: while it includes hemoptysis, a highly predictive
symptom of malignancy [74], evidence from six studies suggests that this
is a relatively rare presenting symptom, reported in less than aquarter (20%-23%) of patients subsequently diagnosed with lung cancer
(Table 2) [36,74–76].
We identified six studies describing the frequencies of the
presenting symptoms of pancreatic cancer (Table S3.9)
[37,43,77–80]. Jaundice has a high predictive value for pancreatic
cancer, but reported frequencies range from 12% to 43% among
patients, and it is often a sign of advanced disease [37,43,77–80]. The
most common presenting symptom among pancreatic cancer patients
is abdominal pain (reported range: 40%-57% of cases), while other
upper gastrointestinal symptoms such as indigestion and nausea and
vomiting are also common—and given their frequency among
primary care consultees, these symptoms have naturally low predictive
values. Studies also reported frequencies of back pain and
nonlocalizing symptoms such as weight loss, lethargy, fatigue, or
malaise among considerable proportions of patients, indicating that
the symptomatic picture of pancreatic cancer is usually a combination
of vague and intermittent symptoms associated with considerable
diagnostic difficulty (Table S3.9).
Current data on the symptom signatures of esophageal and gastric
cancers are limited to studies that describe them in combination
(Table S3.7) [53–56]. While dysphagia is the most common presenting
symptom in this cancer patient population (an alarm symptom shown to
be highly predictive of malignancy), one in two patients present with a
broad spectrum of other symptoms, including abdominal pain, epigastric
pain, reflux, dyspepsia, and systemic symptoms such as nausea or
vomiting, loss of appetite, and weight loss [53–56].
Likewise, ovarian cancer has a symptom signature encompassing a
broad spectrum of abdominal symptoms, although existing evidence
tends to be based on smaller study populations due to the low incidence of
Table 2. Population-Based Estimates of the Frequencies of Presenting Symptoms Among Lung Cancer Patients [36,60,74–76]
Study Setting/Source of Data Study Period Sample Size Study Population
Age/Range
Symptoms
Hamilton et al., 2005a Primary care, data from 21 general practices in Exeter 1998-02 247 40+ years Hemoptysis 20%
Weight loss 27%
Loss of appetite 19%
Dyspnea 56%
Chest or rib pain 42%
Fatigue 35%
Finger clubbing 4.5%
Thrombocytosis 14%
Abnormal spirometry 9.7%
Hippisley-Cox & Coupland, 2011a Primary care, QResearch data (Read coded) 2000-10 2196 30-84 years Hemoptysis 23.0% *
Ades et al., 2014 † Primary care, data from 21 general practices in Exeter 1998-02 247 40+ years Cough 64.8%
Chest pain 40.5%
Redaniel et al., 2015 Primary care, CPRD data (ead coded) 1998-09 5737 15+ years Hemoptysis 8.8%
SVC obstruction 0.4%
Stridor 0.1%
Anorexia 1.7%
Cervical lymphadenopathy 0.5%
Chest signs 2.8%
Chest/rib pain 14.9%
Cough 40.9%
Dyspnea 18.5%
Fatigue 4.1%
Finger clubbing 0.5%
Hoarseness 1.9%
Shoulder pain 5.0%
Walter et al., 2015 Primary & secondary care data; self-reported
symptoms before diagnosis
2010-12 153 40+ years Coughing up blood 21.6%
Cough or worsening cough 56.2%
Breathlessness or worsening breathlessness 41.2%
Chest/ shoulder pain 35.3%
Hoarseness 12.4%
Decreased appetite 22.2%
Unexplained weight loss 15%
Fatigue or tiredness 45.1%
Feeling different “in yourself” 34.6%
SVC, superior vena cava.
* Frequencies of other symptoms included in study were not reported.
† Same study population as Hamilton et al., 2005a; frequencies of additional/different symptoms displayed only.
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shown to have a reasonable predictive value for cancer, but it is only
reported by 8% to 38% of patients before diagnosis; similarly common
presenting symptoms including abdominal bloating and abdominal
pain have much lower predictive values [17]. Additionally, a wide
variety of other symptoms with low predictive values have been
identified as presenting symptoms of ovarian cancer, such as vaginal
bleeding, upper and lower gastrointestinal symptoms, and systemic
symptoms [47,81–83].
Broad Symptom Signature, Low Predictive Value. Some cancers
have broad symptom signatures comprising almost entirely symptoms
of low predictive value. Results from four studies indicate thatTable 3. Population-Based Estimates of the Frequencies of Presenting Symptoms Among Brain or
CNS Cancer Patients [87]
Study Setting/Source
of Data
Study
Period
Sample
Size
Study
Population
Age/Range
Symptoms
Hamilton
et al., 2007
Primary care,
CPRD data
1988-06 3505 18+ years Headache 10.2%
Motor loss 8.8%
New onset seizure 4.4%
Confusion 3.1%
Weakness 2.7%
Memory loss 1.1%
Visual disorder 1.0%hematological cancers (leukemia, lymphoma, and multiple myeloma)
have such symptom signatures, comprised of vague or nonlocalizing
symptoms such as fatigue and weight loss or common complaints
such as back pain (Table S13-15) [33,84–86]. Consequently, some
hematological cancers, and multiple myeloma in particular, are
associated with a high level of diagnostic difficulty, as also evidenced
by high frequency of multiple consultations in primary care before
specialist referral [10].
Although a proportion of patients with brain cancer are diagnosed
after an acute event such as a seizure or neurological deficit, most
patients are thought to initially experience nonspecific symptoms,
with very low predictive value (Table 3) [87]. Achieving earlier
diagnosis of brain and other neurological cancers is therefore
associated with substantial diagnostic difficulties.
How Do Symptoms Relate to Diagnostic Intervals?
To date, there has been limited examination of individual cancer
symptoms and time to diagnosis. The majority of available evidence is
based on the analysis of health records, and symptoms are often
aggregated into broad categories for analysis. For example, patients
with alarm symptoms across a range of cancers have been shown to
experience shorter diagnostic intervals (time from symptomatic
presentation to diagnosis) compared to those with nonalarm
symptoms [23,60,88,89], and similar trends have been noted for
the primary care interval among lung cancer patients [90]. Other
Box 4
Symptoms and time to diagnosis: emerging evidence
Data from three SYMPTOM studies in England on lung, colorectal, and pancreatic cancers provide some early insights into variation in
intervals to diagnosis by individual symptoms [36–38]. Symptom information was collected prospectively from patients before diagnosis
and subsequently combined with information from primary and secondary care data. Investigators identified several symptoms associated
with a shorter interval (e.g., chest or shoulder pain in lung cancer patients), while others were associated with longer time to diagnosis (e.g.,
weight loss in pancreatic cancer) [36–38]. The quantitative examination of presenting symptoms and intervals to diagnosis has also been
enhanced (triangulated) with qualitative analysis of in-depth patient and healthcare professional interviews [93,94].
The multicenter DECCIRE study used a comparable design to collect information on the diagnostic process for 795 colorectal
cancer patients in Spain [95]. Symptom information was elicited from patients shortly after diagnosis by a combination of recall
and recognition, and corroborated with medical records from which prediagnostic intervals were estimated [22]. Of the examined
symptoms, bowel obstruction was the only independent predictor of a shorter diagnostic interval (time from symptom onset to
diagnosis), although investigators noted significant differences in interval length depending on the method of data collection
(patient interview, hospital records, primary care records) [22].
The presenting symptoms of breast cancer and associated patient and primary care intervals have been examined using primary
care data in England [44]. The study documented that women with nonlump breast symptoms, and women with both breast lump
and nonlump breast symptoms sought help later than those who presented with breast lump alone. Risks of recall or selection bias
were minimal, as for the SYMPTOM/DECCIRE studies, and the study had a large representative sample (n = 2316 women) [44].
Further utilization of health records data could enable the investigation of symptom-specific timeliness of presentation and referral
in greater detail.
170 Symptoms and Timeliness in Cancer Patients Koo et al. Neoplasia Vol. 20, No. xx, 2018groupings of presenting symptoms have been used among specific
cancer patient populations, such as lump versus no lump among
either breast or sarcoma patients [91,92].
Available evidence on individual symptoms and diagnostic
timeliness is currently limited to four cancers (breast, colorectal,
lung, pancreatic) and is derived from study designs that combine
prospectively collected patient information with primary and
secondary care records, or examine data collected as part of clinical
audit initiatives (see Box 4). Expanding this line of enquiry to other
cancers is needed, with further consideration of the strengths and
limitations associated with different designs.
Discussion
Measuring presenting symptoms and intervals before the diagnosis of
cancer in patient populations is challenging. Currently, there are two
main approaches: self-report versus records-based information. We
identified 41 population-based studies describing information on the
symptom signatures of 16 common and rarer cancers. Based on our
findings, we described these symptom signatures as narrow (e.g.,
breast, bladder cancers), broad comprising cancers with some highly
predictive symptoms (e.g., colorectal or pancreatic cancer), or broad
comprising cancers characterised by mostly nonspecific symptoms.
Evidence on how presenting symptoms relate to prediagnostic
intervals was limited, but emerging findings indicate notable variation
that could be used to guide interventions.
We have reviewed the interrelated concepts of symptom signature
and diagnostic difficulty, the latter being an expression of
symptom-specific predictive values. It should be acknowledged
however that organizational or system factors can also influence the
difficulty of diagnosis of a particular cancer site. For example, both the
availability and the accessibility of different clinical investigations may
influence the diagnostic difficulty of a cancer. Full blood counts can
be more readily ordered than paraprotein studies in primary care;
therefore, leukemia may be investigated with a lower threshold of
cancer suspicion than myeloma and has lower overall diagnosticdifficulty. Given the likely variation across countries in diagnostic
activity and access to investigations, international comparisons
through collaborative efforts such as the International Cancer
Benchmarking Partnership (ICBP) could be valuable [96].
Further, some presenting symptoms such as jaundice are likely to
represent advanced disease. In these patients, diagnostic difficulty
could be minimal, but expediting their diagnosis may not necessarily
lead to favorable clinical outcomes or alter prognosis. Understanding
associations between symptoms and stage at diagnosis is an important
area for future research [97].
There was substantial variation in reported symptom frequencies
between studies, reflecting the heterogeneity in how symptom
information was reported, extracted, and collated. Optimizing data
capture by improving the application of existing clinical coding systems
(and physician compliance) is important, particularly as novel
technologies such as machine learning and natural language processing
are used to extract information from electronic health records [98–100].
Until we are able to capture population-based information on
symptoms systematically and reliably before diagnosis, existing
methodologies such as clinical audits and prospective cohort studies
offer opportunities to examine the presenting symptoms of cancer and
associated diagnostic intervals [36–38,44].
Many of the studies included in this Review investigated patients
with prespecified symptoms (identified a priori) either from relevant
literature or clinical guidelines. Rarer or less-specific symptoms
might not have been captured and reported symptom frequencies
may not be fully representative of the symptomatic patient
population. Examining all presenting symptoms of a cohort
of cancer patients without prior restrictions can bring valuable
insights [36–38,44,101].Implications for Early Diagnosis Initiatives
Most patients with cancers characterized by a narrow symptom
signature (such as breast and bladder cancer) experience relatively
Neoplasia Vol. 20, No. xx, 2018 Symptoms and Timeliness in Cancer Patients Koo et al. 171short intervals to help-seeking [7–9,32], although a minority of
patients have atypical presentations and experience prolonged
intervals to presentation. Research efforts are needed to improve
timely presentation in the latter group. Further, public health
education campaigns about alarm symptoms remain important for
improving awareness among minority groups and in the context of
low- and middle-income countries [44,102–104]. For cancers with a
broad symptom signature, promoting timely help-seeking is more
challenging. While many patients diagnosed with such cancers will
present with alarm symptoms, many others will present with
symptoms of low predictive value. Thus, while raising awareness of
alarm symptoms associated with those cancers remains important,
complementary strategies need to be developed. Public health
education campaigns could provide information on symptom
combinations or symptom duration, and also address attitudinal
and psychosocial barriers to help-seeking for new symptoms, such as
cancer fear and fatalism [37,105,106].
Postpresentation, patients with alarm symptoms are likely to
benefit from fast-track diagnostic assessment pathways [24,88], but
patients with significant but nonlocalizing symptoms present a greater
challenge. Innovation in diagnostic strategies, either through the
development of new diagnostic tests or novel uses of existing
technologies, is needed. Rapid access to specialist investigative
expertise and testing strategies in the form of multidisciplinary
diagnostic centers (MDCs) have recently been implemented in
Denmark and are currently being developed in the United Kingdom
[107,108]. In addition to improving the diagnosis of cancer, such
services can additionally improve the diagnosis of a range of other
serious (nonneoplastic) diseases [107,109,110]. Further, for patients
with nonresolving vague symptoms of low specificity, planned
reevaluation through safety-netting approaches can minimize pro-
longed time to diagnosis [111].
In conclusion, the diagnostic difficulty of a cancer is closely tied to
its symptom signature. Expanding current scientific knowledge about
the nature of presenting symptoms and how they are associated with
diagnostic intervals will further our understanding of mechanisms
that influence the diagnostic pathway at patient, healthcare
professional, and system levels. Doing so will strengthen the evidence
base to support the development and implementation of public health
and healthcare interventions promoting early diagnosis, thereby
resulting in improved outcomes for cancer patients.Funding
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